Argenx’s Vyvgart Momentum Drives 92% Volume Spike to $280M Ranking 383rd in Market Activity

On August 15, 2025, Argenx (ARGX) traded at 0.21% gains with a trading volume of $0.28 billion, marking a 92.12% surge from the previous day and ranking 383rd in market activity. The biotech firm has seen sustained momentum following a strong quarter for its flagship drug Vyvgart, which is expanding its therapeutic applications in autoimmune diseases. Recent developments highlight Argenx’s strategic advancements in drug formulations and pipeline diversification, positioning it as a key player in the biotech sector.

Argenx’s stock has surged over 31% in the past month, driven by robust performance of Vyvgart and ongoing innovation in treatment modalities. Analysts note that the company’s focus on enhancing its product portfolio and exploring new indications for existing therapies has attracted investor interest. The stock’s recent volume spike suggests renewed speculative activity, though its modest intraday gain reflects a consolidation phase following the rapid rally.

Despite broader market volatility linked to inflation data and geopolitical uncertainties, Argenx remains insulated from cross-sector trends. Its performance is primarily anchored to clinical progress and commercial scalability of Vyvgart. With no major competitors mentioned in the analyzed news, the firm’s near-term trajectory appears tied to execution risks and regulatory updates for its pipeline candidates.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to 2025 yielded a 0.98% average 1-day return, with a cumulative 31.52% gain over 365 days. This indicates that short-term momentum strategies captured some market trends but also exposed investors to volatility and timing risks inherent in high-volume trading.